Sattah Nathan, Zhao Wufan, Choi Alex, Chi Meible, Sarici Kubra, Weng Peter, Morgan Richard, Zheng Yuxi, Karthik Naveen, Vajzovic Lejla, Hadziahmetovic Majda
School of Medicine, Duke University, Durham, NC, USA.
Department of Ophthalmology, Duke University Medical Center, Durham, NC, USA.
J Vitreoretin Dis. 2025 Aug 30:24741264251366393. doi: 10.1177/24741264251366393.
To evaluate the effects of switching from traditional antivascular endothelial growth factor (anti-VEGF) therapies to faricimab, a biclonal antibody that targets both VEGF and angiopoietin-2, on eyes with neovascular age-related macular degeneration (nAMD). This study retrospectively reviewed patients with nAMD who were previously treated with bevacizumab, ranibizumab, or aflibercept and then switched to faricimab. We compared injection frequency and visual acuity (VA) during the time period before faricimab initiation (1 year prior) and after initiation (6-12 months after). Optical coherence tomography images were analyzed from initiation to final follow-up (6-12 months after initiation). We evaluated 84 eyes of 68 patients. Following faricimab initiation, eyes had a reduced mean ± SE central macular thickness (CMT) (282.3 ± 16.2 μm vs 244.8 ± 14.3 μm; < .01). Annual injection frequency increased from 7.73 ± 0.33 to 8.66 ± 0.28 injections ( < .001). VA did not change significantly during the year before faricimab initiation ( = .539) but decreased after initiation (from 0.56 ± 0.05 logMAR to 0.66 ± 0.06 logMAR; < .01). Four eyes developed macular atrophy following faricimab initiation ( < .01). Eyes with nAMD that were previously treated with anti-VEGF therapy and later switched to faricimab showed reduced CMT; however, some patients had increased injection frequency, decreased VA, and macular atrophy. These findings should be explored further using larger datasets.
为评估从传统抗血管内皮生长因子（抗VEGF）疗法转换为法西单抗（一种靶向VEGF和血管生成素-2的双克隆抗体）对新生血管性年龄相关性黄斑变性（nAMD）患者眼睛的影响。本研究回顾性分析了曾接受贝伐单抗、雷珠单抗或阿柏西普治疗后转而使用法西单抗的nAMD患者。我们比较了开始使用法西单抗之前（前1年）和开始使用之后（开始后6 - 12个月）的注射频率和视力（VA）。从开始使用到最终随访（开始后6 - 12个月）对光学相干断层扫描图像进行分析。我们评估了68例患者的84只眼睛。开始使用法西单抗后，眼睛的平均±标准误中心黄斑厚度（CMT）降低（282.3±16.2μm对244.8±14.3μm；P <.01）。年注射频率从7.73±0.33次增加到8.66±0.28次（P <.001）。在开始使用法西单抗前一年，VA没有显著变化（P =.539），但开始使用后下降（从0.56±0.05 logMAR降至0.66±0.06 logMAR；P <.01）。4只眼睛在开始使用法西单抗后出现黄斑萎缩（P <.01）。先前接受抗VEGF治疗后来转而使用法西单抗的nAMD患者的眼睛CMT降低；然而，一些患者注射频率增加、VA下降且出现黄斑萎缩。这些发现应使用更大的数据集进一步探究。
